• Wondering if Revolution Medicines at around US$142.51 is still offering value after its strong run, or if you are late to the story? This article focuses squarely on what the current price could mean for you as a shareholder.
• The stock has seen a 1.1% decline over the last 7 days, but that comes after strong gains of 48.0% over 30 days, 80.3% year to date, 240.0% over 1 year and a very large 3 year return of 456.2% and 5 year return of 363.6%.
• Recent headlines around Revolution Medicines have focused on its position in biotech and investor interest in its pipeline progress, which helps explain why the stock has attracted so much attention this year. This backdrop is important context when you weigh up whether the recent share price path has moved too far away from underlying value.
• On Simply Wall St's valuation checks, Revolution Medicines currently has a value score of 2 out of 6. Next you will see how that score plays out across different valuation approaches, and then finish with a way of thinking about value that goes beyond any single model.

Revolution Medicines scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Revolution Medicines Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model projects a company’s future cash flows and then discounts them back to today’s value, giving an estimate of what the stock could be worth based on those cash flows.

For Revolution Medicines, the latest twelve month Free Cash Flow is a loss of about $1.07b. Analysts have provided Free Cash Flow estimates out to 2030, with Simply Wall St extrapolating beyond the initial analyst horizon using a 2 Stage Free Cash Flow to Equity model. Within these projections, Free Cash Flow for 2030 is estimated at about $2.55b, with interim years moving from losses in 2026, 2027 and 2028 to positive cash flow from 2029 onward.

Discounting all of those projected cash flows back to today produces an estimated intrinsic value of about $497.07 per share. Compared with the current share price of around $142.51, the model suggests the stock trades at a 71.3% discount to this intrinsic value. On these assumptions, this points to a materially undervalued DCF outcome.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Revolution Medicines is undervalued by 71.3%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Revolution Medicines Price vs Book

For companies that are not yet consistently profitable, earnings based metrics like the P/E ratio are less useful, so investors often look at balance sheet based measures such as Price to Book (P/B). This compares the stock price to the company’s net assets per share.

In general, higher growth expectations or lower perceived risk can justify a higher “normal” P/B multiple, while lower growth or higher risk often means a lower multiple is considered reasonable. Revolution Medicines currently trades on a P/B of about 20.20x. This sits well above the Biotechs industry average of roughly 2.39x and the peer group average of about 10.10x.

Simply Wall St’s “Fair Ratio” is a proprietary estimate of what the P/B multiple could be, given factors such as earnings growth outlook, profit margins, industry, market cap and company specific risks. Because it incorporates these company level drivers, it provides a more tailored reference point than a simple comparison with peers or the broad industry. In this case, Revolution Medicines does not yet have a Fair Ratio available, so the P/B comparison alone cannot clearly indicate whether the stock is overvalued or undervalued.

Result: ABOUT RIGHT

P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Revolution Medicines Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives are introduced here as your short, clear story about Revolution Medicines that links what you think about its RAS(ON) pipeline, future revenue, earnings and margins to a forecast and then to a Fair Value. All of this takes place within Simply Wall St’s Community page where millions of investors share their views. You can, for example, lean toward a more optimistic Narrative closer to the US$170 Fair Value or a more cautious one nearer US$92, compare that Fair Value with the current price to help decide whether you see the stock as attractive or not right now, and have that view automatically refreshed as new news, earnings or clinical data are incorporated into the underlying numbers.

For Revolution Medicines however, here are previews of two leading Revolution Medicines narratives to help frame your analysis:

Fair Value: US$170.00

Implied discount to this Fair Value versus the current US$142.51 price: about 16%.

Analyst revenue forecast used in this narrative: about 1,184.41% growth.

• Focuses on RAS(ON) oncology catalysts including 8 Phase III trials, multiple FDA breakthrough therapy designations and combination regimens that could broaden usage across several tumor types.
• Builds on a strong cash position of about US$2.03b plus up to US$2b from Royalty Pharma to support extensive R&D and commercial build out before any product revenue.
• Assumes revenue of US$2.1b and earnings of US$424.4m by 2029, with the stock trading on a P/E of 117.4x, and encourages you to test whether those assumptions feel reasonable.

Fair Value: US$133.70

Implied premium to this Fair Value versus the current US$142.51 price: about 7%.

Analyst revenue forecast used in this narrative: about 902.29% growth.

• Highlights that the company is still pre revenue with guided 2026 GAAP operating expenses of US$1.6b to US$1.7b, so cash use and timing of any approvals are key for future earnings.
• Emphasizes concentration in RAS targeted oncology, execution risk across multiple large Phase III programs and the possibility that competing therapies or resistance patterns could limit the long term opportunity.
• Works off a consensus Fair Value of US$133.70 that implies earnings of US$148.6m by 2029 and a P/E of 263.8x, and asks you to decide whether that combination of growth, margin and valuation assumptions feels demanding or reasonable.

Once you have a feel for which narrative is closer to your own view, you can use that as the lens for interpreting the current US$142.51 share price, the DCF result and the P/B comparison, and then consider how Revolution Medicines fits into your wider portfolio and risk tolerance.

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Revolution Medicines on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Do you think there's more to the story for Revolution Medicines? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.